33

PATIENT EDUCATION HANDOUT


Cervical Cancer Screening


David Crownover, MD; Alicia Lunardhi, OMS-IV; Amanda Frugoli, DO, FACOI; Lynn Kong, MD

Paula Gregory, DO, MBA, FACOFP, Editor • Lindsay Tjiattas-Saleski, DO, MBA, FACOEP, Associate Editor


WHAT IS CERVICAL CANCER?

Cancer can develop anywhere atypical cells divide without regulation (in an uncontrolled manner). In women, this can occur on the uterine cervix, which connects the vagina and uterus.


The cancer can lead to tumor formation on the cervix and, as it advances, the cancer can enter local organ structures or spread outside the reproductive system.1 The American Cancer Society estimates that in 2022, there will be about 14,100 new cases and 4,280 women will die from cervical cancer.1 Cervical cancer can occur in women at any age but is more common after age 40.


Risk factors for cervical cancer include the following2:


WHAT IS HUMAN PAPILLOMAVIRUS?

Human papillomavirus is a virus that spreads through vaginal, anal, or oral sex and can lead to changes within the cells in your body. Many HPV infections are asymptomatic,1 meaning, they don’t cause symptoms, but over time they can result in abnormal changes to your cells. This can develop into cervical cancer as well as anal, vulvar, penile, or head and neck cancers.2 Many sexually active people will have a genital HPV infection in their lifetime. In 2013–2014, high-risk genital HPV was found in about 45% of adults.3 Some types of HPV are more likely to lead to cancer than others. Lower-risk HPV types can lead to genital warts.


You can protect yourself against HPV through vaccination. Vaccination works best if a person completes the series of vaccines before sexual activity begins. It is still helpful before a person is sexually active and potentially exposed to HPV and can also be given after a person has been sexually active. People can get vaccinated for HPV at any time, from ages 9–26 (it has been FDA approved for people up to 45 years old). The ideal age for HPV vaccination is around 11–12 years old. The vaccine requires 2 doses given 6–12 months apart.4



DOWNLOAD AND DISTRIBUTE

The PDF of this patient education handout is available for easy download and distribution to your patients at www.acofp.org/PEH.

The Osteopathic Family Physician Patient Handout is a public service of ACOFP. The information and recommendations appearing on this page are appropriate in many instances; however, they are not a substitute for medical diagnosis by a physician. For specific information concerning your medical condition, ACOFP suggests that you consult your family physician. This page may be photocopied noncommercially by physicians and other healthcare professionals to share with their patients.


WOMEN'S HEALTH

34 Osteopathic Family Physician | Volume 14, No. 6 | November/December 2022



HOW DO YOU SCREEN FOR CERVICAL CANCER?

Cervical cancer is a slow-growing cancer. Precancerous cell changes can be detected with regular screening. Deaths from cervical cancer have dropped significantly because of the increased use of the Pap test.1 A Pap test looks for abnormal cells in the cervix. Pap tests can also be combined with an HPV test that detects high-risk HPV types, which are associated with an increased risk of cervical cancer. Regular screening can detect precancerous changes and lead to early intervention. Cervical cancer screening can be done by your family medicine or primary care doctor or by your obstetrician-gynecologist.

THE SCREENING GUIDELINES ARE BELOW5:

If you are less than 21 years old: no screening.

If you are 21–29 years old: Pap test every 3 years.

If you are 30–65 years old:

° have a history of cervical cancer or moderate-to-severe cervical changes, you should continue screening for 20 years after your surgery; or

° have no history of cervical cancer or cervical changes, you do not need screening.

You will begin by lying down on your back on the exam table and placing your feet in the stirrups at the end of the table and relaxing your knees outward. Your doctor will insert a speculum with lubricant into your vagina to hold the vaginal walls open. This will allow the doctor to see your cervix and use a small brush to collect cells from your cervix.


If you have any questions before your Pap test, be sure to ask your doctor.


UNDERSTANDING YOUR CERVICAL CANCER SCREENING RESULTS

Normal is normal! Follow the screening guidelines above for the next time you should screen again.


There are many ways a Pap smear and HPV test could come back as abnormal. An HPV test may come back positive. With a Pap smear, if any abnormal cells are found, they may fall into the following categories6:


° CIN 1: mild changes that usually resolve on their own

° CIN 2: moderate changes

° CIN 3: severe changes


SOURCE(S):

  1. American Cancer Society. Key Statistics for Cervical Cancer. Accessed November 4, 2022. https://www.cancer.org/cancer/cervical-cancer/about/key-statistics.html

  2. American Cancer Society. Cervical Cancer. Accessed March 15, 2022. https://www.acog.org/womens-health/faqs/cervical-cancer

  3. McQuillan G, Kruszon-Moran D, Markowitz LE, Unger ER, Paulose-Ram R. Prevalence of HPV in adults aged 18–69: United States, 2011–2014. NCHS data brief, no 280. National Center for Health Statistics; 2017. Accessed November 6, 2022. https://www.cdc.gov/nchs/products/databriefs/db280.htm

  4. Centers for Disease Control and Prevention. Vaccines and Preventable Diseases. Human papillomavirus (HPV) vaccination: what everyone should know. Published November 24, 2021. Accessed November 6, 2022. https://www.cdc.gov/vaccines/vpd/hpv/public/index.html

  5. US Preventive Services Task Force, Curry SJ, Krist AH, Owens DK, et al. Screening for cervical cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;320(7):674–686. doi:10.1001/jama.2018.10897

  6. Perkins RB, Guido RS, Castle PE, et al; 2019 ASCCP Risk-Based Management Consensus Guidelines Committee. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors:

J Low Genit Tract Dis. 2020;24(2):102–131. doi:10.1097/LGT.0000000000000525